Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 133.27M | 22.39M | 44.99M | -228.17M | -223.68M |
| Total Depreciation and Amortization | 1.40M | 1.56M | 1.68M | 1.80M | 1.80M |
| Total Amortization of Deferred Charges | 2.57M | 2.50M | 2.43M | 2.45M | 2.07M |
| Total Other Non-Cash Items | 101.80M | 104.00M | 109.07M | 108.36M | 115.97M |
| Change in Net Operating Assets | -201.27M | -85.12M | -79.30M | 120.06M | 95.54M |
| Cash from Operations | 37.77M | 45.33M | 78.86M | 4.49M | -8.29M |
| Capital Expenditure | -305.00K | -313.00K | -225.00K | -77.00K | -118.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -305.00K | -313.00K | -225.00K | -77.00K | -118.00K |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 365.45M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.70M | 8.90M | 9.28M | 11.04M | 9.63M |
| Repurchase of Common Stock | -26.00K | -11.00K | -26.00K | -36.00K | -36.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -5.63M | -5.63M | -333.75M |
| Cash from Financing | 8.67M | 8.88M | 3.63M | 5.37M | 41.30M |
| Foreign Exchange rate Adjustments | 760.00K | 1.25M | 101.00K | 252.00K | -91.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.90M | 55.15M | 82.36M | 10.04M | 32.80M |